We are live on ! Find out more
BCLSI

Bain Capital Life Sciences Investors Portfolio holdings

AUM $1.11B
1-Year Est. Return 171.34%
This Fund
S&P 500
This Quarter Est. Return
-13.27%
1 Year Est. Return
+171.34%
3 Year Est. Return
+643.23%
5 Year Est. Return
+451.99%
10 Year Est. Return
–
AUM
$676M
AUM Growth
-$174M
Cap. Flow
+$18.7M
Cap. Flow %
2.77%
Top 10 Hldgs %
90.65%
Holding
26
New
–
Increased
2
Reduced
2
Closed
2

Top Buys

Rank Stock Value
1
SLDB icon
Solid Biosciences
SLDB
+$16.6M
2
SVRA icon
Savara
SVRA
+$8.38M

Top Sells

Rank Stock Value
1
OLMA icon
Olema Pharmaceuticals
OLMA
+$3.15M
2
MRNS
Marinus Pharmaceuticals, Inc
MRNS
+$1.44M
3
NAUT icon
Nautilus Biotechnolgy
NAUT
+$1.02M
4
SYRS
Syros Pharmaceuticals, Inc. Common Stock
SYRS
+$632K

Sector Composition

Rank Sector Weight
1 Healthcare 99.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MRNS
26
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
– –
-2,693,380
Closed -$1.44M
1
2

Similar funds

JTWM
Jackson Thornton Wealth Management Montgomery, Alabama $1.11B AUM 22.53% 1-Year Est. Return
HH
Hilltop Holdings Dallas, Texas $1.11B AUM 24.7% 1-Year Est. Return
RIM
Rockbridge Investment Management Syracuse, New York $1.11B AUM 13.62% 1-Year Est. Return
YL
YCG LLC Austin, Texas $1.1B AUM 4.87% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AIM
Advyzon Investment Management Lisle, Illinois $1.12B AUM 22.08% 1-Year Est. Return
MTCM
Mint Tower Capital Management Amsterdam, Netherlands $1.12B AUM 18.84% 1-Year Est. Return
CNC
Canandaigua National Corp Canandaigua, New York $1.12B AUM

Bain Capital Life Sciences Investors's Q1 2025 Portfolio in Review

As of Q1 2025, Bain Capital Life Sciences Investors held 26 positions worth $676M, down 20% from $850M the previous quarter. Its ten largest holdings account for 91% of the portfolio.

Bain Capital Life Sciences Investors's Q1 2025 filing shows 2 increased, 2 reduced and 2 closed positions. The largest sale was Olema Pharmaceuticals, an estimated $3.15M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Bain Capital Life Sciences Investors added most to Solid Biosciences in Q1 2025, an estimated $16.6M increase.
  • Bain Capital Life Sciences Investors's biggest Q1 2025 reduction was Olema Pharmaceuticals, cutting an estimated $3.15M.
  • Bain Capital Life Sciences Investors fully exited Marinus Pharmaceuticals, Inc in Q1 2025, selling an estimated $1.44M.
  • Bain Capital Life Sciences Investors's ten largest holdings make up 91% of its $676M portfolio in Q1 2025.
  • Bain Capital Life Sciences Investors opened 0 new positions and closed 2 in Q1 2025.
  • Bain Capital Life Sciences Investors's portfolio value fell 20% quarter-over-quarter to $676M.

Based on Bain Capital Life Sciences Investors's 13F filing for Q1 2025, filed 15 May 2025.